Kymera Investor Day Presentation Deck
KT-474 MAD4/200mg Reduced IRAK4 to Near LLOQ in the Skin (MS)
IRAK4 Levels in Skin vs PBMC at Day 14
of KT-474 treatment
Mean (± SE) Absolute IRAK4 Levels
[fmol/µg protein]
0.20
0.15
0.10
0.05
0.00
KYMERA
1
Baseline levels 5- to 10-
fold lower than PBMC
●
Absolute IRAK4 Levels in Skin
●
●
7
*
14
Day
Placebo
25 mg QD
50 mg QD
100 mg QD
200 mg QD
©2021 KYMERA THERAPEUTICS, INC.
LLOQ
Mean (± SE) Absolute IRAK4 Levels
[fmol/µg protein]
0.6
0.4
0.2
0.0
28
* Data beyond day 14 pending
• Baseline IRAK4 levels in skin substantially lower compared to PBMC
Dose-dependent IRAK4 degradation in skin by mass spectrometry
Steady-state degradation not yet reached at day 14
Mean IRAK4 levels at 200 mg dose nearing LLOQ by Day 14, with knockdown up to 90% at 200 mg
Comparable degradation in PBMC shows that effect of KT-474 is independent of baseline expression level
Placebo
25 mg QD 50 mg QD
KYMERA R&D DAY - December 16th, 2021
100 mg QD
Plasma
Skin
200 mg QD
LLOQ
PAGE 38View entire presentation